Tradewinds Capital Management LLC Has $989,000 Stock Holdings in Abbott Laboratories (NYSE:ABT)

Tradewinds Capital Management LLC lifted its stake in Abbott Laboratories (NYSE:ABT) by 228.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,745 shares of the healthcare product maker’s stock after purchasing an additional 6,080 shares during the period. Tradewinds Capital Management LLC’s holdings in Abbott Laboratories were worth $989,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. International Assets Investment Management LLC grew its position in shares of Abbott Laboratories by 13,194.9% in the 3rd quarter. International Assets Investment Management LLC now owns 1,679,805 shares of the healthcare product maker’s stock valued at $191,515,000 after purchasing an additional 1,667,170 shares during the period. Silver Oak Securities Incorporated increased its position in shares of Abbott Laboratories by 44.7% during the third quarter. Silver Oak Securities Incorporated now owns 7,111 shares of the healthcare product maker’s stock worth $799,000 after acquiring an additional 2,197 shares in the last quarter. Trueblood Wealth Management LLC raised its holdings in shares of Abbott Laboratories by 4.3% during the third quarter. Trueblood Wealth Management LLC now owns 5,588 shares of the healthcare product maker’s stock worth $637,000 after acquiring an additional 232 shares during the period. Tarbox Family Office Inc. lifted its position in Abbott Laboratories by 2.9% in the 3rd quarter. Tarbox Family Office Inc. now owns 52,187 shares of the healthcare product maker’s stock valued at $5,950,000 after acquiring an additional 1,447 shares in the last quarter. Finally, Country Club Bank increased its holdings in Abbott Laboratories by 2.1% during the 3rd quarter. Country Club Bank now owns 22,481 shares of the healthcare product maker’s stock worth $2,528,000 after purchasing an additional 469 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have commented on ABT. Evercore ISI boosted their target price on Abbott Laboratories to $136.00 and gave the company a “buy” rating in a research note on Thursday, January 2nd. Wells Fargo & Company increased their target price on shares of Abbott Laboratories from $133.00 to $136.00 and gave the stock an “overweight” rating in a report on Thursday, January 23rd. Barclays reiterated an “overweight” rating and issued a $158.00 price target (up from $149.00) on shares of Abbott Laboratories in a research note on Monday, January 27th. Argus upgraded Abbott Laboratories to a “strong-buy” rating in a report on Tuesday, January 28th. Finally, StockNews.com lowered Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 12th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $133.06.

Abbott Laboratories Trading Up 1.4 %

Shares of Abbott Laboratories stock opened at $135.04 on Friday. The firm’s 50-day moving average price is $120.75 and its two-hundred day moving average price is $116.88. The company has a market capitalization of $234.22 billion, a price-to-earnings ratio of 17.65, a PEG ratio of 2.48 and a beta of 0.75. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $135.41.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 earnings per share for the quarter, hitting the consensus estimate of $1.34. Abbott Laboratories had a return on equity of 20.74% and a net margin of 31.95%. The firm had revenue of $10.97 billion during the quarter, compared to analysts’ expectations of $11.03 billion. During the same period in the prior year, the company earned $1.19 earnings per share. The company’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be issued a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 30.85%.

Insider Activity

In related news, EVP Daniel Gesua Sive Salvadori sold 23,771 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $128.50, for a total transaction of $3,054,573.50. Following the sale, the executive vice president now owns 125,697 shares in the company, valued at $16,152,064.50. The trade was a 15.90 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.10% of the stock is currently owned by corporate insiders.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.